Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kadmon Reveals A Bit Of Its Hand To Investors

This article was originally published in The Pink Sheet Daily

Executive Summary

Kadmon CEO Sam Waksal - the former CEO of ImClone - laid out the startup's ambitious pipeline during the Jeffries Healthcare Conference.

You may also be interested in...



Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle

Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).

Back In Biotech, Waksal's Kadmon Emerges From Stealth Mode To Focus on Hep C

Deal with Valeant brings development and commercialization rights to ribavirin analog that could have better safety profile for anemia.

Regeneron Leaders On Getting A Call From Trump And Building A Bioreactor Farm

Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel